Medical specialists in Brazil are warning consumers against purchasing injectable GHK-Cu peptides sold through online marketplaces [1].
This alert comes as the product gains popularity for hair loss treatment, despite lacking regulatory clearance from the Brazilian Health Regulatory Agency, known as Anvisa [1]. The use of unapproved injectable substances poses significant health risks, including the potential for severe hepatic injury [1].
The peptide GHK-Cu has been marketed in some circles as a booming new solution for hair loss [2]. Some reports indicate the treatment was highlighted as a success at the AMWC congress in Monaco [2]. However, these claims of efficacy contrast with the warnings from health professionals regarding the safety of the injectable versions currently available online [1].
Doctors said that the lack of Anvisa approval means the product has not undergone the necessary safety and quality screenings required for medical use in Brazil [1]. Because these products are sold via online channels, they often bypass the pharmaceutical oversight intended to protect patients from contaminated or improperly dosed substances [1].
The primary concern for medical specialists is the risk of liver damage [1]. Injecting substances that have not been vetted by regulatory bodies can lead to unpredictable systemic reactions — some of which may be irreversible [1].
While the peptide is presented by some outlets as a promising cosmetic breakthrough [2], the medical community emphasizes that the risk of toxicity outweighs the anecdotal benefits of unapproved versions [1].
“Injectable GHK-Cu has no Anvisa approval and may cause liver damage.”
The conflict between promotional claims at international congresses and local regulatory warnings highlights a growing trend of 'biohacking' and the rapid spread of unapproved medical treatments via e-commerce. When cosmetic peptides bypass national health agencies like Anvisa, consumers assume the risk of toxicity and contamination without professional medical supervision.
